58 related articles for article (PubMed ID: 38608143)
1. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
2. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer.
Abdullah S; Chakraborty R; Kumkar PS; Debnath B; Bala A
J Environ Pathol Toxicol Oncol; 2024; 43(3):13-38. PubMed ID: 38608143
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathology of Primary Non-small Cell Lung Cancer.
Suster DI; Mino-Kenudson M
Arch Med Res; 2020 Nov; 51(8):784-798. PubMed ID: 32873398
[TBL] [Abstract][Full Text] [Related]
5. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010.
Felip E; Gridelli C; Baas P; Rosell R; Stahel R;
Ann Oncol; 2011 Jul; 22(7):1507-1519. PubMed ID: 21536661
[TBL] [Abstract][Full Text] [Related]
6. Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer.
Ionescu DN; Stockley TL; Banerji S; Couture C; Mather CA; Xu Z; Blais N; Cheema PK; Chu QS; Melosky B; Leighl NB
Curr Oncol; 2022 Jul; 29(7):4981-4997. PubMed ID: 35877256
[TBL] [Abstract][Full Text] [Related]
7. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
8. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
9. Advanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendations.
Kuykendall A; Chiappori A
Cancer Control; 2014 Jan; 21(1):67-73. PubMed ID: 24357744
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
